Class / Patent application number | Description | Number of patent applications / Date published |
514559000 | Ring containing | 57 |
20080214668 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE - This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient. | 09-04-2008 |
20080234376 | EMULSION COMPOSITION COMPRISING PROSTAGLANDIN E1 - An emulsion composition includes prostaglandin E | 09-25-2008 |
20080275118 | HEALTH AND COSMETIC COMPOSITION AND REGIME FOR STIMULATING HAIR GROWTH AND THICKENING ON THE HEAD, INCLUDING THE SCALP, EYELASHES, AND EYEBROWS, AND WHICH DISCOURAGES HAIR LOSS - This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and/or hair loss prevention agent, and a hair and/or skin lightening and/or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the composition of the invention can be used with dyed/treated hair so as to not affect the color of the hair. | 11-06-2008 |
20080319071 | Novel Nutraceutical and Pharmaceutical Compositions and Use Thereof for the Treatment, Co-Treatment or Prevention of Inflammatory Disorders - The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders. | 12-25-2008 |
20090012165 | PHARMACEUTICAL COMBINATION OF NSAID AND PROSTAGLANDIN COMPOUND - Provided is a method for treating a condition or disease which is one of the indications for NSAID use, which comprises administering a combination of:
| 01-08-2009 |
20090023810 | METHODS OF TRANSLATION AND/OR INFLAMMATION BLOCKADE - The present invention relates to a method of translation or inflammatory response blockade by using a compound that binds to eIF4A, which is the 264 | 01-22-2009 |
20090036530 | Crystalline acid of lipoxin A4 analogs and method of making - This invention is directed to a crystalline acid of a lipoxin A | 02-05-2009 |
20090124694 | METHOD OF PRODUCING RETINYL ESTERS - A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester. | 05-14-2009 |
20090124695 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS - A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions. | 05-14-2009 |
20090170944 | OPHTHALMIC MICELLAR COMPOSITIONS WITH ENHANCED STABILITY - This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16, wherein the pharmaceutically active substance exhibits an improved stability. In particular, a composition is provided that comprises cetalkonium chloride micelles incorporating the prostaglanding-like therapeutic agent, latanoprost. This invention also relates to ophthalmic compositions containing such micellar compositions and methods of using these ophthalmic compositions for the treatment of eye conditions. | 07-02-2009 |
20090197953 | Pharmaceutical composition for the specific treatment of acute myeloid leukemia - The present invention provides the use of all-trans retinoic acid for the production of a pharmaceutical composition for the treatment of acute myeloid leukemia, which use is characterized in that the patients are selected from the group of non-M3 acute myeloid leukemia patients according to a physiologic concentration, e.g. a level of MN1 below a certain critical level analysed in total blood cells, preferably analysed in bone marrow cells. The critical level of MN1 can be determined according to known methods, e.g. by specific determination of the presence of MN1, e.g. using specific anti-MN1 antibody, e.g. in an ELISA or in another immuno specific assay. Preferably, the level of MN1 is determined at its transcription level, e.g. as the concentration of mRNA encoding MN1. | 08-06-2009 |
20090203784 | TREATMENT REGIMEN FOR N-MYC, C-MYC, AND L-MYC AMPLIFIED AND OVEREXPRESSED TUMORS - The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors, comprising administering multiple therapeutic compounds like DFMO, SAM486A, a verinoid and a cytotoxic drug and placing the patient on a low polyamine diet and/or providing the patient with a polyamine limiting dietary supplement. | 08-13-2009 |
20090203785 | METHOD AND PROCESS FOR PRODUCING YOUTHFUL-APPEARING, SMALL-PORED, AND SMOOTH SKIN - A method and process for producing youthful appearing, small-pored, and smooth skin by pre-treating the skin topically with retinoic acid, applying carbon particles on the skin, removing the carbon particles by exploding them with laser light, and post-treating the skin topically with retinoic acid. When treating the face, removing the carbon particles requires only about 4 minutes. The laser light itself does not injure the skin. Treatment by explosion of the carbon particles stimulates the production of collagen in the high dermis leaving the epidermis intact, with no removal of stratum corneum. Repeated intermittent treatments of exploding carbon particles and topical application of retinoic acid to the skin produce the desired results in the skin indefinitely as long as the treatment and applications are continued. | 08-13-2009 |
20090281184 | PHARMACEUTICAL FOR PREVENTION AND TREATMENT OF OPHTHALMIC DISEASE INDUCED BY IN-CREASE IN VASOPERMEABILITY - A medicament for preventive and/or therapeutic treatment of an ocular disease resulting from vascular hyperpermeability, for example diabetic retinopathy or age-related macular degeneration, which comprises as an active ingredient a retinoid such as all trans retinoic acid or 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid. | 11-12-2009 |
20100022645 | PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases - The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. | 01-28-2010 |
20100029765 | TOPICAL AQUEOUS COMPOSITION COMPRISING TRETINOIN - Topical aqueous compositions for the treatment of a skin disorder particularly acne. Topical aqueous composition comprising tretinoin and a hydrophilic cellulose derivative as a gelling agent, wherein the composition has a pH of about 4 to about 6.5 and viscosity of less than about 20,000 cP or provided. The composition also relates to the topical administration of tretinoin in combination with an antibiotic. | 02-04-2010 |
20100069491 | LIPID-AMINO ACID CONJUGATES AND METHODS OF USE - N-fatty acid-amino acid conjugates and J | 03-18-2010 |
20100087532 | MODULATION OF SIGNAL TRANSDUCTION - A polypeptide is identified as being functionally included in a signal transduction pathway having a biological effect. Contemplated polypeptides are different from a retinoic acid receptor, a retinoid X receptor, or a cellular retinoic acid binding protein, however bind a retinoid or retinoid metabolite, and binding of the retinoid or retinoid metabolite lead to a modulation of the biological effect. In particularly contemplated methods, a retinoid or retinoid metabolite is administered to a cell or mammal in a concentration effective to modulate the biological effect. | 04-08-2010 |
20100113596 | Method for inhibiting liver fibrosis via retinoic acid derivative - Transforming growth factor-beta1 (TGF-β1) mediates expression of collagen 1A2 (Col 1A2) gene via a synergistic cooperation between Smad2/Smad3 and Sp1, both act on the Col 1A2 gene promoter. The present invention discloses a method for inhibiting liver fibrosis via a retinoic acid derivative primarily extracted from the mycelia of | 05-06-2010 |
20100204327 | Methods for making retinoids and uses thereof - Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof. | 08-12-2010 |
20100210727 | HEPOXILIN ANALOG ENANTIOMERS - The present invention relates to enantiomeric forms of hepoxilin analogs of Formula I-VIII, pharmaceutical compositions thereof, a method for the separation of said enantiomeric forms of hepoxilin analogs comprising applying said hepoxilin to a chiral phase HPLC column and eluting said hepoxilin with an alkane and alcohol solvent mixture. Said enantiomeric forms of hepoxilin analogs of Formula I-VIII were found to be useful in controlling the biological effects of PPAR mediated transcriptional control for the treatment of diseases such as cancer, thromboxane-mediated diseases and for modulating intracellular calcium concentration. | 08-19-2010 |
20110039930 | FAST-ACTING NAPROXEN COMPOSITION WITH REDUCED GASTROINTESTINAL EFFECTS - The present invention relates to pharmaceutical formulations containing Naproxen and a delivery agent. | 02-17-2011 |
20110190395 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT - The present disclosure relates to lipid compounds of general formula (I) wherein R | 08-04-2011 |
20110275715 | METHOD FOR TREATING RETINAL DISEASE - The present application provides a method for treating a retinal disease in a patient in need thereof, which comprises administering at least three drops of an ophthalmic composition comprising a fatty acid derivative as an active ingredient in an eye of the patient per day. | 11-10-2011 |
20120010288 | Method for protecting a retinal neuronal cell - A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2α derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient. | 01-12-2012 |
20120115954 | Aqueous retinoid and benzoyl peroxide gel - Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid. | 05-10-2012 |
20120178812 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives - Pharmaceutical formulations containing lipoic acid derivatives are made. | 07-12-2012 |
20120270945 | METHOD FOR MODULATING CYTOKINE ACTIVITY - The present invention relates to a method for modulating cytokine activity, immunomodulation or treating esophagitis comprising an administration of a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating cytokine activity, immunomodulation or treating esophagitis comprising a fatty acid derivative. | 10-25-2012 |
20120316240 | METHOD OF DIAGNOSIS - Disclosed herein are methods that generally to the fields of pharmaceutical chemistry, biochemistry, molecular biology and medicine. More particularly, aspects of the invention concern methods to identify a predisposition for fibrosis in a biological sample, methods of identifying agents that modulate the onset of fibrosis, methods of making a formulation that inhibits the onset or progression of fibrosis, and methods of monitoring the progression of fibrosis or the efficacy of a fibrosis treatment. | 12-13-2012 |
20120316241 | REMEDY FOR CARTILAGE-RELATED DISEASES - The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease. | 12-13-2012 |
20120316242 | METHODS OF TREATING METABOLIC DISORDERS - A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β/δ of the cells. | 12-13-2012 |
20130012582 | VINYLIC MASK WITH PEEL-OFF EFFECT FOR TOPICAL USE CONTAINING HIGH CONCENTRATIONS OF RETINOIC ACID - A formulation for topical use having a filmogenic (peel-off) action for professional and home use, containing high concentrations of Retinoic acid, the method of production and use thereof in the treatment of acne, wrinkles, hyperpigmentations, psoriasis and all imperfections linked to keratinization disorders. The composition also comprises octyldodecyl octyldodecanoate, and polyvinyl alcohol. The composition is in the form of a face mask (pack). | 01-10-2013 |
20130143966 | METHODS OF TREATMENT USING STERCULIC ACID - The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-keto-cholesterol toxicity, and unregulated angiogenesis. | 06-06-2013 |
20130150445 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives - Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer. | 06-13-2013 |
20130158119 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - Pharmaceutical semi-solid composition of Isotretinoin An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 06-20-2013 |
20130184348 | SKIN ACTIVATION BY ACCELERATION OF PDGF-BB ACTIVITY - This method, which screens drugs that activate the skin, is characterized by causing candidate drugs to act on vascular endothelial cells, and selecting drugs that enhance the expression of PDGF-BB by the cells as a skin activation agent. | 07-18-2013 |
20130217769 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 08-22-2013 |
20130217770 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME BY ADMINISTRATION OF CHLORIDE CHANNEL OPENER - A chloride channel opener, especially a prostaglandin compound, is used for the treatment of functional gastrointestinal disorders. The prostaglandin compound can be, for example, a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E | 08-22-2013 |
20130225683 | Compounds and Pharmaceutical Compositions for Uses in Diabetes - New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders. The related pharmaceutical compositions and methods are also described. These compounds can be used in combination with comprising a therapeutic agent for lowering or controlling blood glucose level such as metformin or a thiazolidinedione. | 08-29-2013 |
20130317106 | METHODS FOR MAKING RETINOIDS AND USES THEREOF - Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof. | 11-28-2013 |
20140057982 | RETINOIDS AND USE THEREOF - The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders. | 02-27-2014 |
20140066506 | METHOD FOR TREATING MACULAR DEGENERATION - Disclosed is a method for treating macular degeneration in a mammalian subject, which includes administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F | 03-06-2014 |
20140094519 | LIPOXIN ANALOGS AS NOVEL INHIBITORS OF ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 04-03-2014 |
20140107203 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C. | 04-17-2014 |
20140121275 | Method of Feeding Livestock to Improve Carcass Characteristics - Feeding a diet supplemented with DDGS or another supplement containing UFA at a level above a threshold to animals such as swine, cattle, and poultry can have negative effects on carcass fat, certain growth parameters, and meat characteristics. However, if this diet is provided with a second supplement that contains CPFA at specified levels in the diet, the negative effects otherwise expected are wholly or at least partially countered. The invention recommends employing a supplemental source of CPFA between about 0.001% and about 0.5% of the diet by weight. Negative effects on carcass characteristics caused by ractopamine can also be countered by the addition of this amount of at least one source of CPFA in the diet. | 05-01-2014 |
20140163102 | MEDICAL DRESSING FOR RESPIRATORY EPITHELIAL CELLS - The present invention provides a medical dressing for respiratory epithelial cells comprising a biocompatible polymer and retinoic acid, wherein, based on total volume of the dressing, the polymer is 99% or more, and retinoic acid is 1% or less. | 06-12-2014 |
20140200274 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE - In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day. | 07-17-2014 |
20140303251 | Methods Of Treating Acute Kidney Injury With Retinoic Acid - The present invention provides, in one embodiment, a method of inhibiting apoptosis in kidney epithelial cells after acute injury by modulating/inhibiting Nur77 induction/expression or function/activity in the cells. The invention further provides a method of preventing or treating an acute kidney injury in a subject in need thereof, comprising administering to the subject an effective amount of a retinoic acid or retinoic acid derivative, and a method of preserving a kidney for transplant, comprising contacting the kidney with a solution that comprises a retinoic acid or a, retinoic acid derivative. | 10-09-2014 |
20140343145 | RBP1 as a Molecular Biomarker for Predicting Survival and Response to Treatment in Glioma - Disclosed herein are methods for detecting the presence of an isocitrate dehydrogenase mutation in a sample from a subject. Also disclosed are methods diagnosing and treating subjects having a cancer including determining whether the cancer may likely be treated with one or more retinoids. | 11-20-2014 |
20140350106 | Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same - Compositions and methods for urea silicone gels for treating skin conditions that may benefit from barrier protection and from urea silicone gel ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gel may be excessive dryness, insect bites, keloids and scars, among others. Disclosed urea silicone gel may include micronized urea USP, an anhydrous silicone base, and a PEG ointment base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol that may increase skin permeability to urea. PEG ointment base may be water-washable and includes meadowsweet extract. Additionally, PEG urea silicone gel may provide occlusion, and may maintain a moist environment within the skin condition which allows optimal healing. Pain also may be decreased by maintaining a moist environment. | 11-27-2014 |
20150011633 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES - Pharmaceutical formulations containing lipoic acid derivatives are made. | 01-08-2015 |
20150057351 | METHOD FOR TREATING NEUROPATHIC PAIN - A method for treating neuropathic pain in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative, is provided. | 02-26-2015 |
20150290163 | RETINOIC ACID MICRONEEDLE - An object to be achieved by the present invention is to provide a microneedle array which is able to supply effectively retinoic acid to the skin and effective in treating pimples, stains or wrinkles. | 10-15-2015 |
20160074346 | METHOD OF VIRAL INHIBITION - This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV. | 03-17-2016 |
20160106697 | METHODS FOR MAKING RETINOIDS AND USES THEREOF - Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof. | 04-21-2016 |
20160122820 | Screening Method for Identifying Active Agents - The present invention relates generally to screening methods, and in particular, screening methods for identifying active agents having therapeutic or cosmetic benefits to the human integumentary system. The invention also relates to compositions for topical application to the skin comprising active agents identified by the screening methods of the invention, and to methods for improving the health and/or appearance of skin by topically administering to the skin compositions comprising active agents identified by the screening methods of the invention. | 05-05-2016 |
20160128962 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 05-12-2016 |